Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) CEO Amir Heshmatpour purchased 50,000 shares of Neonc Technologies stock in a transaction dated Tuesday, November 10th. The shares were bought at an average price of $4.19 per share, with a total value of $209,500.00. Following the completion of the transaction, the chief executive officer owned 3,313,000 shares in the company, valued at approximately $13,881,470. This trade represents a 1.53% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Neonc Technologies Price Performance
Shares of NTHI stock opened at $4.52 on Thursday. The firm has a 50-day moving average price of $3.30 and a 200 day moving average price of $5.31. Neonc Technologies Holdings, Inc. has a twelve month low of $2.50 and a twelve month high of $12.00.
Neonc Technologies (NASDAQ:NTHI – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.03).
Analysts Set New Price Targets
View Our Latest Stock Report on Neonc Technologies
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE purchased a new position in shares of Neonc Technologies during the 2nd quarter valued at $1,017,000. BlackRock Inc. purchased a new stake in shares of Neonc Technologies during the second quarter worth $815,000. Westmount Partners LLC raised its holdings in shares of Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after acquiring an additional 153,858 shares in the last quarter. Finally, Global Retirement Partners LLC acquired a new stake in Neonc Technologies during the second quarter valued at $126,000.
About Neonc Technologies
NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.
Featured Stories
- Five stocks we like better than Neonc Technologies
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
